This article is a correction to:
Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
Qingyue Zeng
Jiao Xu
Xingyu Mu
Yi Shi
Hong Fan2*- 1General Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
- 2Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China
by Zeng Q, Xu J, Mu X, Shi Y, Fan H and Li S (2023) Front. Endocrinol. 14:1214334. doi: 10.3389/fendo.2023.1214334
In the published article, there was an error in affiliation 1. Instead of “Department of General Practice Medicine Center, West China Hospital, Sichuan University,Chengdu, China,”, it should be “General Practice Ward/International Medical Center Ward, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.”
In the published article, there was an error in the Funding statement. The statement was originally as follows: “The authors declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University (Grant Number Z2021JC005).” The correct Funding statement appears below.
“The authors declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Sichuan Science and Technology Program (No. 2017SZYZF0002 and No. 2021YFH0168).”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: dual agonists, incretin based therapy, tirzepatide, type 2 diabetes, obesity, glucagon-like peptide-1 receptor agonists
Citation: Zeng Q, Xu J, Mu X, Shi Y, Fan H and Li S (2024) Corrigendum: Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front. Endocrinol. 15:1342543. doi: 10.3389/fendo.2024.1342543
Received: 22 November 2023; Accepted: 06 March 2024;
Published: 14 March 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Zeng, Xu, Mu, Shi, Fan and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shuangqing Li, 1259594471@qq.com; Hong Fan, fanhongfan@qq.com
†These authors have contributed equally to this work and share first authorship